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ABSTRACT
Objectives: To study if genes with common single nucleotide polymorphisms (SNPs)
associated with obesity-related phenotypes influence weight loss (WL) in obese individuals
treated by a hypo-energetic low-fat or high-fat diet.
Design: Randomised, parallel, two-arm, open-label multi-centre trial.
Setting: Eight clinical centres in seven European countries.
Participants: 771 obese adult individuals.
Interventions: 10-wk dietary intervention to hypo-energetic (600 kcal/d) diets with a
targeted fat energy of 20%–25% or 40%–45%, completed in 648 participants.
Outcome Measures: WL during the 10 wk in relation to genotypes of 42 SNPs in 26
candidate genes, probably associated with hypothalamic regulation of appetite, efficiency of
energy expenditure, regulation of adipocyte differentiation and function, lipid and glucose
metabolism, or production of adipocytokines, determined in 642 participants.
Results: Compared with the noncarriers of each of the SNPs, and after adjusting for gender,
age, baseline weight and centre, heterozygotes showed WL differences that ranged from0.6
to 0.8 kg, and homozygotes, from0.7 to 3.1 kg. Genotype-dependent additional WL on low-
fat diet ranged from 1.9 to 1.6 kg in heterozygotes, and from 3.8 kg to 2.1 kg in
homozygotes relative to the noncarriers. Considering the multiple testing conducted, none of
the associations was statistically significant.
Conclusions: Polymorphisms in a panel of obesity-related candidate genes play a minor role,
if any, in modulating weight changes induced by a moderate hypo-energetic low-fat or high-fat
diet.
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INTRODUCTION
Obesity has a joint genetic and environmental etiology [1].
Rare cases of severe, early onset obesity have been attributed
to single gene mutations with large functional effect [2]. The
genetic inﬂuence on obesity may be because of combinations
of multiple genes with individual small effect sizes related to
frequent single nucleotide polymorphisms (SNPs). These may
interact mutually and with the environment in a complex
manner to inﬂuence obesity [2,3]. Numerous gene variants
have been reported to be associated with obesity or obesity-
related phenotypes [4], but only a few of the associations have
been replicated in other populations [2,4].
It is conceivable that the effect of some genes on the
obesity phenotypes may be nutrient-sensitive. Indeed, diet
composition and/or energy intake may modulate gene
expression through complex transcriptional mechanisms as
well as more downstream processes involving the gene
products [2,3]. Several studies have clearly demonstrated that
expression of multiple genes in adipose tissue is altered by
reductions in energy intake, but so far none has revealed an
inﬂuence of the dietary composition in this setting [3,5,6].
The implications for human health of alterations in these
processes by common genetic polymorphisms are still elusive,
but they may be revealed by showing that the effect of the diet
on weight changes depends on differences in the genes, and
this could also help explain discrepancies in the association
studies.
However, few gene-nutrient interaction studies of obesity
and weight change have been carried out in humans, and the
results have been ambiguous, whether being based on either
epidemiological, observational, and cross-sectional studies
[3,7] or small experimental over-feeding studies [8]. A few
studies [3], including twin studies [9], suggest that genes play a
role in weight loss (WL) as the outcome of dietary treatment
of obesity. These genes could be the same genes as those
involved in obesity, exempliﬁed by a study of the relation
between variation in the MC4R gene, the most common form
of monogenic obesity [2,10], and the outcome of surgical
treatment [11]. However, twin studies of the two pheno-
types—degree of obesity and WL—show that the genetic
correlation for these phenotypes is far from 1.0, implying that
it is only a subset of the genes that are the same behind the
genetic inﬂuence on either of the two phenotypes [12].
A possibly useful approach to elucidate the role of the
genes and diets in obesity would be to study effects of genetic
polymorphisms on WL induced by speciﬁc dietary treatments
of obesity. The NUGENOB Consortium (Nutrient-Gene
Interactions in Human Obesity: Implications for Dietary
Guidelines) has conducted a randomised intervention trial of
a 10-wk low-fat or high-fat hypo-energetic diet (with ﬁxed
protein content and a corresponding high or low carbohy-
drate content) in obese individuals from eight centres in
seven European countries with the speciﬁc purpose of
studying aspects of gene-nutrient interaction (for more on
the NUGENOB project, see http://www.nugenob.org) [13].
This trial showed that the low-fat diet produced the same
mean WL as the high-fat diet, but resulted in more
participants losing .10% of initial body weight and had
fewer dropouts [13].
The aim of the present study was to investigate, using the
NUGENOB trial [13], if genetic polymorphism modulates WL
induced by either a low- or a high-fat hypo-energetic diet.
Common SNPs in a panel of obesity-related candidate genes
were selected on the basis of their known or presumed
involvement in various parts of the pathogenic processes of
obesity and its related phenotypes.
METHODS
The study was a randomised, parallel, two-arm, open-label,
10-wk intervention by two hypo-energetic diets with either
low or high fat content, undertaken at eight sites in seven
European countries. The clinical parts of the trial are
described in detail in a previous publication [13].
Participants and Baseline Investigation
We planned to recruit 100 Caucasian Europeans from each of
seven centres and 50 from one other centre, and included
during the period May 2001 through September 2002 in total
771 participants (579 women) from the United Kingdom
(Nottingham), the Netherlands (Maastricht), France (Paris
and Toulouse), Spain (Pamplona), Czech Republic (Prague),
Sweden (Stockholm), and Denmark (Copenhagen).
The study aimed at recruiting participants with a body
mass index (BMI) greater than or equal to 30 kg/m2 and age
20–50 y, and without weight change more than 3 kg within the
3 mo prior to the study start. Participants reporting clinically
diagnosed hypertension, diabetes or hyperlipidæmia treated
by drugs, untreated thyroid disease, surgically or drug-treated
obesity, pregnancy, or alcohol or drug abuse were excluded.
Participants not included in other trials were recruited
www.plosclinicaltrials.org June | 2006 | e120002
Genetics and Dietary Weight Loss
Editorial Commentary
Background: Obesity is an important cause of death and disease,
particularly in the developed world. It is understood that both
environmental and genetic factors contribute towards obesity. Numer-
ous studies have associated particular gene variants with a tendency
towards obesity, but it is not known whether such gene variants affect
the degree to which obese individuals will lose weight when dieting.
What this trial shows: As part of a randomised trial, 771 participants
were assigned to one of two different low-energy diets for 10 weeks: one
low in fat or one high in fat. The researchers then did a genetic analysis
of 642 participants completing the intervention, to find out whether any
of 42 distinct genetic variations in 26 genes were associated with weight
loss in the trial. The genetic variants were chosen for study as they were
known or already thought to be associated with appetite regulation or
various aspects of metabolism and fat tissue development and function.
The investigators found that none of the genetic variants studied had a
significant association with weight loss in the trial. It was also seen that
the majority of genetic variants were not associated with efficacy of one
dietary intervention over another.
Strengths and limitations: Although a large number of participants was
recruited into the trial, the genetic analysis involved multiple compar-
isons—168 tests of 42 genetic variants. This increases the likelihood that
any significant associations found could have resulted from chance
alone. Significant associations from this study will require additional
confirmation in larger studies.
Contribution to the evidence: This study adds data indicating that
variation in the genes studied did not have an important influence on
weight loss.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.
through local sources as available and convenient. The ethical
committee at each of the participating centres approved the
study. Volunteers were informed about the nature of the
study, and written consent was obtained prior to study
participation.
Before assignment to the dietary intervention group, all
participants underwent a thorough standardised clinical and
physiological examination described in Standard Operational
Procedures applied in all participating centres (see Trial
Protocol and Annexes). Each examination included blood
sampling, and measurement of height with a calibrated
stadiometer and weight (in light indoor clothes and without
shoes) with a calibrated set of scales. Resting metabolic rate
was measured by a ventilated hood system.
Blood drawing and processing of blood samples were
performed according to international guidelines for genetic
studies [14]. Whole blood was drawn in sterile vacutainer
tubes with ethylenediaminetetraacetic acid. The plasma was
removed, and the white cell layer (the buffy coat) was
transferred to cryovials and frozen at 80 8C.
Interventions
The target macronutrient composition of the two diets was:
low-fat diet: 20%–25% of total energy from fat, 15% from
protein and 60%–65% from carbohydrate; high-fat diet: 40%–
45% of total energy from fat, 15% from protein, and 40%–
45% from carbohydrate. Both diets were designed to provide
600 kcal/d fewer than the individually estimated energy
requirement, which was based on pre-treatment resting
metabolic rate multiplied by a physical activity level of 1.3,
assuming a sedentary life style. The dietary programme is
described in detail on the Web site http://www.nugenob.org.
The dietary instructions also aimed at minimising differences
between the two diets in other components such as source
and type of fat, amount and type of ﬁbre, type of
carbohydrate, amount of fruit and vegetables, and in meal
frequency patterns, while taking local customs into account
as appropriate. Participants were requested to abstain from
alcohol consumption. The dietary instructions were rein-
forced and monitored and participants were weighed weekly.
Participants were advised to follow their habitual activity
patterns throughout the dietary intervention period. A 3-d,
weighed food record of two weekdays and one weekend day
was obtained before the study and during the last week of the
intervention. One-day weighed food records were completed
during the second, ﬁfth, and seventh weeks. The dietary
records were analysed using the country-speciﬁc food-
nutrient database routinely used in each centre. The nutrient
composition of the baseline diet was the average across the 3d
of recordings, and the composition of the intervention diet
was based on averaging across all the dietary recordings
during the intervention period (Table 1).
Objectives
The objectives of the clinical trial were to assess the effect on
WL in obese participant of a low-fat versus a high-fat hypo-
energetic diet. The objectives of the present analysis were to
investigate if the genotypes of 42 SNPs in 26 candidate genes,
probably associated with hypothalamic regulation of appe-
tite, efﬁciency of energy expenditure, regulation of adipocyte
differentiation and function, lipid and glucose metabolism,
or production of adipocytokines, inﬂuenced the WL, possibly
dependent on which of the two diets the participants were
prescribed.
Outcomes
The outcomes in the present analysis were the WL during the
10-wk dietary intervention in the various genotype groups
deﬁned by the SNPs in the selected genes.
The selection of candidate genes was based on their
.......................................................................................................................................................................................
Table 1. Baseline and 10-wk Measurements of Body Weight, Body Mass Index, Energy Intake, and Macronutrient Energy Percent of
the Diet (without Alcohol Energy Percent) in 642 European Obese Individuals Who Completed Dietary Intervention
Measurement Group High-Fat Dieta Low-Fat Dietb
Baseline Decrease Baseline Decrease
Body weight (kg) Women 97.0 (13.8) 6.2 (3.3) 96.6 (15.1) 6.7 (3.1)
Men 111.0 (14.8) 8.2 (3.5) 110.3 (17.6) 7.7 (4.0)
All 100.5 (15.3) 6.7 (3.5) 100.1 (16.9) 6.9 (3.4)
Body mass index (kg/m2) Women 35.7 (4.6) 2.3 (1.2) 35.8 (4.9) 2.5 (1.1)
Men 34.9 (4.3) 2.6 (1.1) 34.5 (4.8) 2.4 (1.3)
All 35.5 (4.6) 2.4 (1.2) 35.5 (4.9) 2.5 (1.2)
Energy intake (kcal/d) Women 2,043 (568) 528 (536) 2,047 (550) 601 (531)
Men 2,677 (724) 715 (637) 2,692 (917) 805 (895)
All 2,199 (667) 574 (567) 2,209 (717) 653 (647)
Fat energy percent in diet Women 36.5 (7.7) 4.3 (8.5) 36.4 (7.0) 11.9 (7.8)
Men 37.3 (8.1) 3.9 (9.9) 37.0 (8.4) 11.0 (8.8)
All 36.7 (7.8) 4.2 (8.9) 36.6 (7.4) 11.7 (8.1)
Carbohydrate energy percent in diet Women 45.7 (8.8) 3.6 (9.4) 45.7 (7.9) 11.5 (8.7)
Men 42.7 (8.5) 1.6 (9.8) 43.9 (9.9) 12.0 (9.8)
All 44.9 (8.6) 3.1 (9.5) 45.3 (8.5) 11.6 (9.0)
Protein energy percent in diet Women 16.5 (3.6) 0.6 (3.9) 16.7 (3.8) 1.4 (4.2)
Men 16.9 (3.2) 0.2 (3.0) 16.3 (3.2) 1.4 (3.2)
All 16.6 (3.5) 0.5 (3.7) 16.6 (8.7) 1.4 (4.0)
Baseline values and decreases are means (SD).
an¼ 232 women, 76 men.
bn¼ 249 women, 85 men.
DOI: 10.1371/journal.pctr.0010012.t001..
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potential contribution to obesity-related phenotypes, their
presumed nutrient-sensitive expression and function of the
gene products, and the presence of common SNPs with a
presumed allele frequency above 0.05 allowing meaningful
analysis of the interaction between diet and its effect on WL.
The SNPs were selected through mutation analysis of genes
found by positional cloning, mutation analysis of plausible
biological candidate genes selected from the literature and
found to be associated with functional effects of the gene
products, and the available pertinent knowledge about
already known obesity-related SNPs [2].
On this basis, 42 SNPs in 26 genes known or presumed to
be associated with hypothalamic regulation of appetite,
efﬁciency of energy expenditure, regulation of adipocyte
differentiation and function, lipid and glucose metabolism,
or production of several adipocytokines were selected [15–
54]. Table 2 lists the genes and the SNPs analysed, and they
are grouped according to their presumed function in relation
to the obesity phenotypes. It appears from the positions of
the SNPs that some may have functional effects by changing
the gene products, some may affect the promoter function,
and others may be in linkage disequilibrium with other SNPs
with functional effects. Since all selected SNPs have been
found in previous studies to be associated with obesity-
related phenotypes, they may be considered tag SNPs of
potentially functional haplotypes irrespective of their own
presumed functional effects in relation to the obesity-related
phenotypes or the currently addressed induced WL. For
several of the genes selected (ENPP1, GAD2, CART, SLC6A14,
GHRL, PCSK1, ADIPOQ, and WAC) a linkage disequilibrium
analysis secured an optimal coverage of the genetic variation
known at the time of gene selection. For this reason, these
SNPs were considered the risk SNPs, and the participants not
carrying these SNPs were denoted ‘‘noncarriers’’ correspond-
ing to ‘‘wild types’’ irrespective of which alleles were most
frequent in the present study.
For each genotype, four genetic models were analysed. In
the ﬁrst general genetic model, there were no assumptions
made about a speciﬁc effect of the mutant alleles in the
individuals who were heterozygous and homozygous for the
gene variant when compared with those who were noncarrier
(null hypothesis). Three speciﬁc genetic models assume a
particular effect of the gene variant compared with the
noncarrier: dominant effect (noncarrier ¼ 0, heterozygous
and homozygous ¼ 1), co-dominant effect (assessed as an
additive effect: noncarrier¼ 0, heterozygous¼ 1, homozygous
¼ 2), and recessive effect of gene variant (noncarrier ¼ 0,
heterozygous¼ 0, homozygous¼ 1). For some of the variants,
the homozygotes were so rare (less than 10 homozygotes in 7
out of the 42 SNPs) that identiﬁcation of recessive trans-
mission or distinction between dominant and co-dominant
transmission would not be possible (Table 2).
Genotyping
Samples of buffy coat, drawn at baseline, were sent to the
Steno Diabetes Centre in Copenhagen on dry ice, where DNA
was extracted. Extracted DNA samples were diluted in Tris/
EDTA buffer to a stock DNA solution of 100 ng/ll and a
working DNA solution of 10 ng/ll. Stock solutions were
stored at80 8C, working solutions were stored at 4 8C. DNA
samples were stored and handled in locations free of
contaminating polymerase chain reaction products.
Forty of the 42 SNPs in the 26 genes were genotyped by the
LightCycler assay (Roche Diagnostics, Basel, Switzerland) (the
SLC6A14, CART, GHSR, GAD2, GHRL, LEPROTL1, UCP2,
UCP3, WAC, LIPC, IGF2, ENPP1, ADIPOQ, and CD36 genes)
based on hybridization probes labelled with ﬂuorescent dyes
that allow ﬂuorescence resonance energy transfer [55] or by
TaqMan assay (Applied Biosystems, Foster City, California,
United States) (the MKKS, PCSK1, FOXC2, PPARGC1A,
PPARG2, PPARG3, SREBF1, HSD11B1, KCNJ11, IL6, TNFa,
and SERPINE1 genes). Sequences of primers pairs, labelled
with ﬂuorescein and LC Red 640 are available on request
from the authors. One SNP in IGF2 (6815 A.T) and one in
CART (3608 T.C) were genotyped by direct sequencing. No
genotyping could be carried out in seven out of the 771
participants enrolled in the study, and in ﬁve out of those
completing the intervention. The genotyping success rate was
92.8%–98.8% except for WAC (89.2%) and SERPINE1
(86.6%).
Sample Size
For a single analysis, the least detectable effect (WL, in kg) was
estimated by the programme QUANTO version 1.0 (see http://
hydra.usc.edu/gxe) with the assumptions of a statistical power
of 0.80, a sample size of 642 individuals, and a mean WL of 6.8
kg with a SD of 3.5 kg. For allele frequencies ranging from
0.05–0.50, the least detectable WL of main effects of genes
ranged from 1.30–0.78 kg (0.89 kg for an allele frequency of
0.50) for dominant models, from 7.72–0.89 kg for recessive
models, and from 1.25–0.55 kg for additive co-dominant
models. Assuming, in addition, equal distribution of partic-
ipants between the diets, the least detectable effects on WL of
gene-diet interaction, modelled as speciﬁed above, ranged
from 2.59–1.54 kg (1.77 kg for allele frequency of 0.50) for
dominant models, from 15.5–1.77 kg for recessive models, and
from 2.49–1.07 kg for additive co-dominant models.
When assuming that testing for each SNP in each genetic
model is a testing of the same null hypothesis multiple times,
the needed sample size increases. Thus, as an example,
detection of a signiﬁcant difference of 1.5 kg between the
low-fat and high-fat diets in heterozygotes and a difference of
3.0 kg between the diets in homozygotes versus that observed
in noncarriers at an alpha level of 0.05, and a statistical power
of 0.80 with four genetic models for 42 SNPs (168 tests of the
same null hypothesis) would require sample sizes ranging
from 5,729 through 1,008 participants in the trial for allele
frequencies ranging from 0.05 through 0.50, respectively.
Randomisation
Stratiﬁed block randomisation was used with centre, gender,
and three age groups (20–29 y, 30–39 y and 40–50 y) as strata
and a block size of 12. The randomisation list was computer-
generated and the block size was unknown to the clinical
centres. Individual randomisation was carried out at the co-
ordinating centre following transfer from the clinical centres
of the relevant baseline information on the participants.
Statistical Methods
Examination of Hardy-Weinberg equilibrium was carried out
by applying a global test for all genotypes (using the
HWE.GENEPOP programme) [56], and a test for each
genotype by taking into account centre differences by
summing up Pearson v2 statistics for each centre and
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comparing with a v2 distribution with 8 degrees of freedom.
Genotype distributions in various subgroups (eligible versus
noneligible, women versus men, randomised diet groups, and
completers versus noncompleters of the intervention) were
compared by the Pearson v2 statistics as appropriate. The
primary outcome in the present analysis was mean WL (in kg)
with 95% conﬁdence intervals (CI), conditional on genotype
and assigned diet. The WL was calculated as the difference
between weight recorded immediately before randomisation
and the weight at the completion of the intervention
programme. Differences in body weight changes were
compared by regression models, in which we controlled for
centre (Gaussian random effect), gender, age (linear and
squared), and baseline weight (linear) separately for men and
women. The distributions of the residuals were compatible
with the normal distribution and this was veriﬁed by the
Shapiro-Wilk test.
The regression model addressing the effects of the
genotypes on WL—main effects assessed in one model for
each genotype—included the genotypes for each variant as
covariates and as a separate covariate, the diet group to which
the participants had been randomised. The gene–diet
interaction analysis was carried out by estimating for each
genotype the difference in WL, adjusted by the regression
model as described, between the low-fat group (lf) and the
high-fat (hf) group, and then comparing the differences in
WL by diet group for a particular genetic variant (ga) and the
noncarrier (gn); using the indicated notation, the outcome
variable expressing the interaction would be derived from
this equation: [WL(lf, ga) – WL (hf, ga)] – [WL(lf, gn) – WL(hf,
gn)]. Hence, a positive value of an estimated WL difference
indicates a greater WL on the low-fat diet than on the high-
fat diet in individuals carrying the particular gene variant
than in noncarriers of the variant.
For all the genes in which genotyping was carried out for
more than one SNP (see Table 2), haplotype-based analysis
was carried out by the programme GENECOUNTING
(version 1.3) [57], which implements an Expectation Max-
imisation algorithm for estimation of the haplotype proba-
bilities in unrelated participants without reference to the
phenotype. Subsequently, we estimated the relation between
the possible haplotypes on each chromosome and WL by
using haplotype pairs for each participant as covariates in
regression models with WL as outcome. This was carried out
by multiple imputations. In each of 1,000 imputations, a new
dataset was generated where the haplotype pairs for each
participant were drawn at random according to the hap-
lotype probabilities for all the possible haplotypes for each
individual as estimated by the GENECOUNTING pro-
gramme. The imputed datasets are each analysed by the
same univariate model; the WL differences and its variances
were estimated based on the method of imputation, and a test
for departure from no association was constructed [58]. This
approach exploits the entire information on possible
haplotypes for each participant in contrast to conventional
methods selecting for each individual only the most probable
haplotype, implying that all other less likely haplotypes are
discarded.
The statistical signiﬁcance was set at p , 0.05, but as
mentioned above, the interpretation of the signiﬁcance level
must take into account that testing is performed for two
different types of hypotheses (gene effects on WL as such, and
gene 3 diet interaction), four different types of genetic
models (unspeciﬁed, dominant, co-dominant, and recessive)
and 42 different SNPs (i.e., in 2 3 168 ¼ 336 partially
dependent analyses). Although no adequate formal correc-
tion for multiple testing is available for this scenario, any
apparently statistically signiﬁcant outcome of single tests
must be considered tentative, requiring independent repli-
cation in other studies.
The statistical software SPSS version 11.5 (SPSS, Chicago,
Illinois, United States); SAS version 8.2 (SAS Institute, Cary,
North Carolina, United States); and STATA version 8.0 (Stata,
College Station, Texas, United States), were used as appro-
priate.
RESULTS
Patient Flow and Numbers Analysed
The outcome of the dietary intervention trial has been
reported in detail elsewhere [13]. Out of the 771 obese
individuals enrolled in the trial, 648 completed the dietary
intervention, and genotype data were available in 643 of these
participants because of lack of DNA or genotyping failure in
5 participants.
In this group, 129 individuals (20.1%) exhibited character-
istics deviating from the recruitment criteria, predominantly
because of lower baseline BMI (range 26.4–29.9, mean 29.2) in
35 individuals (5.5%) or weight instability during the last 3
mo before enrolment in 73 (11.4%), but they were all kept in
the present analysis because there were no prior reasons to
assume that this would affect the results of the analyses. One
participant was considered an outlier by having a combina-
tion of an excessively great BMI (66.1 kg/m2; all others were
below or equal to 56 kg/m2) and increase in body weight
during the intervention, which affected the underlying basic
regression model. Therefore, the present analyses were based
on 642 individuals. The relation between the originally
recruited 771 participants and the distribution on the
randomised groups are shown in Figure 1.
Baseline Data
There were only minor differences in the distributions of
genotypes between this group and those who did not
complete the intervention (unpublished data). The distribu-
tion of the genotypes on noncarriers, heterozygotes and
homozygotes, the allele frequencies, and the outcome of
testing for Hardy-Weinberg equilibrium are shown in Table
2. All allele frequencies exceeded 0.05 except for GSHR447
C.G, which, however, was retained in the analysis. As
expected, it appears that the frequencies of homozygotes
for a number of alleles were so small that analysis of
associations with speciﬁc genetic models would be impossible
or very uncertain as also indicated in the estimated least
detectable effects above. The global test for Hardy-Weinberg
equilibrium of all genotypes showed no signiﬁcant departures
within each centre. As seen in Table 2, the test for each
individual genotype showed that all SNPs barring three
(GAD2, þ83897 T.A; ADIPOQ, þ276 T.G; and TNFa, 308
G.A) were in Hardy-Weinberg equilibrium, but in view of
the unsuspicious and minor departure from the equilibrium,
these SNPs were kept in the analysis. The genotype
distributions showed no or small differences (none of which
was statistically signiﬁcant after appropriate adjustment for
www.plosclinicaltrials.org June | 2006 | e120007
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multiple testing), between men and women, between the two
diet groups, or between the (in retrospect) eligible and
noneligible groups (unpublished data), and it was therefore
not considered necessary when testing each of the genotypes
to adjust for the other genotypes.
Total energy intake and dietary fat energy percent during
the interventions were within the targeted intervals (Table
1). Mean WL was 6.9 kg in the low-fat group, and 6.7 kg in
the high-fat group, with no signiﬁcant group difference
(mean 0.3 [95% CI, 0.3 to 0.8] kg), and this corresponds
closely to the WL expected from the dietary energy
restriction. The two diet groups did not differ in baseline
and decrease in fat body mass, lean body mass, waist
circumference, hip circumference and fasting insulin, nor
in glucose levels [13]. The blood-lipid proﬁles differed as
expected from the differences in diet composition (the low-
fat diet group had greater decline in plasma cholesterol,
plasma low-density lipoprotein cholesterol, and plasma high-
density lipoprotein cholesterol, and less decline in plasma
triacylglycerol), which supports that the dietary intervention
did achieve the desired difference in the diet consumed [13].
There was, however, a considerable unexplained interindi-
vidual variation in WL within both groups, with standard
deviations of 3.4 kg and 3.5 kg in the low-fat and high-fat
groups, respectively (Table 1), which could be caused by
genetic differences.
Outcomes and Estimation
Genetic effects on WL. Table 3 shows the results of the
analysis of effects of genotypes on WL while controlling for
the diet group (main effects of genotypes) without specifying
genetic models. The table presents the difference in WL
between the groups of participants who are heterozygous and
homozygous for the risk SNPs and those who are homozygous
noncarriers of the risk alleles, which thus is the reference
group and therefore not depicted. None of the genotypes had
statistically signiﬁcant inﬂuence on WL in general. The
effects in heterozygotes, compared with noncarriers, ranged
from 0.6 to 0.8 kg, and all the CI’s overlapped or included
0.0 kg. The effects in homozygotes ranged from0.7 to 3.1 kg,
and all CIs overlapped 0.0 kg. All analyses of the general
effects of the haplotypes on WL were nonsigniﬁcant
(unpublished data), except for those of ENPP1 (p ¼ 0.04),
see below.
Gene-diet interaction effects on WL. Table 4 shows the
outcome of the analyses of effects of gene-diet interaction on
WL, i.e., the possible effects of genotype on the efﬁcacy of the
particular dietary intervention. If there were no interaction
between the particular genotype and the dietary interven-
tion, then the differences in WL between the dietary groups
for each genotype would be the same, and the ﬁgures in the
table would be 0.0 kg, whereas a value for the estimated WL
signiﬁcantly departing from 0.0 kg would indicate a gene-diet
interaction. Positive ﬁgures mean that the WL is greater on
the low-fat than with the high-fat diet when the risk SNP is
present than when it is not present (noncarrier), and vice-
versa for negative ﬁgures. As in Table 3, those who are
noncarriers of the risk SNPs are the references groups and
thus not depicted.
The genotype-dependent excess WL on low-fat diet
compared with high-fat diet ranged from 1.9 to 1.6 kg in
heterozygotes, and from 3.8 kg to2.1 kg in homozygotes, but,
except for association with one SNP in ADIPOQ (11377
C.G) and the SNP of the TNFa, none were signiﬁcant. These
two test results would not be statistically signiﬁcant if the
multiple testing related to Table 4 was taken into account.
None of the haplotype analyses showed any overall
statistically signiﬁcant effects, and judged from the CI, none
of the individual haplotypes was statistically signiﬁcant.
Ancillary Analyses
Speciﬁc genetic models and speciﬁc haplotypes. In single tests
signiﬁcant association (p , 0.05) with WL was found for the
SNPs of the genes PCSK1, WAC, HSD11B1, and TNFa, when
assuming speciﬁc genetic models, and these ﬁndings are
summarised in Table 5.
For the GAD2 gene, the global analysis of the haplotypes
was not signiﬁcant, but there was one haplotype, composed of
a combination of all three risk SNPs, which compared with
the haplotype without any risk SNPs, showed a borderline
effect according to the CI (Table 5). The effect of the
haplotype in which only the ENPP1 SNP 1044 A.G was
present with the other loci without the risk SNPs appeared to
be the main contributor to the signiﬁcant effect compared
with the haplotype including none of the risk SNPs (Table 5).
When assuming speciﬁc genetic models in the analyses of
the dietary interactions with the genotypes, we found few
statistically signiﬁcant (p , 0.05) interaction effects for
Figure 1. Patient Flow in the Trial
DOI: 10.1371/journal.pctr.0010012.g001
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variants in the SLC6A14, KCNJ11, ENPP1 (1044 A.G),
ADIPOQ (11391 G.A) and TNFa genes (Table 5).
None of the results shown in Table 5 was adjusted for
multiple testing effects, which would have made all results
statistically insigniﬁcant.
Adverse Events
As reported previously, there were no adverse events [13].
Dropouts were because of changes in personal circumstances,
dislike of the diets, and emerging health problems unrelated
to the diets.
DISCUSSION
Interpretation
This study aimed at utilising the randomised dietary
intervention as an experimental approach to investigate
whether the effects of a panel of 42 SNPs in 26 candidate
genes are associated with diet-induced WL, and whether these
effects are sensitive to the fat (versus the carbohydrate)
content of a hypo-energetic diet. All the genes are known or
presumed to be associated with obesity-related phenotypes or
to be involved in pathophysiological processes implicated in
obesity. The overall conclusion from the analyses is that there
.......................................................................................................................................................................................
Table 3. Differences in Weight Loss (WL) by Genotypes (with the Noncarrier Reference) following 10-wk Dietary Intervention, Aiming
at Reducing the Energy Intake by 600 kcal in 642 European Obese Women and Men
Gene Single Nucleotide
Polymorphism (SNP)
Heterozygous Homozygous Single SNP
Test
Haplotype
Testb
WLa CI WLa CI p p
SLC6A14 Women þ22510 C.G 0.1 (0.7,0.9) 0.1 (0.9,0.8) 0.90
SLC6A14 Men þ22510 C.G — — 0.7 (1.9,0.5) 0.27
CART 3608 T.C
1702 C.T
175 A.G
1336 delA
0.5
0.5
0.5
0.6
(0.1,1.2)
(0.1,1.1)
(0.1,1.2)
(1.3,0.1)
0.1
0.2
0.0
1.9
(0.8,0.6)
(0.9,0.5)
(0.7,0.7)
(0.6,4.5)
0.09
0.07
0.09
0.06
0.91
GHSR 447 C.G 0.1 (1.3,1.1) — — 0.87
GAD2 þ83897 T.A
þ61450 C.A
243 A.G
0.5
0.1
0.3
(1.0,0.1)
(0.6,0.4)
(0.9,0.3)
0.4
0.5
0.6
(1.5,0.8)
(1.4,0.4)
(1.8,0.6)
0.27
0.56
0.40
0.33
GHRL Leu72Met 0.3 (0.5,1.1) 0.7 (3.9,2.4) 0.64
MKKS Arg517Cys 0.6 (0.1,1.2) 1.1 (5.1,7.3) 0.22
LEPROTL1 2625 C.T 0.5 (0.3,1.4) 0.2 (6.4,6.1) 0.49
PCSK1 T690S C.G 0.5 (1.1,0.0) 0.5 (1.4,0.5) 0.14
UCP2 866 G.A 0.3 (0.8,0.2) 0.0 (0.8,0.8) 0.45
UCP3 55 C.T 0.0 (0.5,0.6) 0.5 (0.4,1.5) 0.56
FOXC2 512 C.T 0.2 (0.6,1.0) 0.3 (0.4,1.1) 0.68
PPARGC1A Gly482Ser
þ2962A/G
0.7
0.5
(0.2,1.5)
(0.1,1.0)
0.3
0.6
(0.5,1.1)
(0.1,1.3)
0.23
0.18
0.14
PPARG2 Pro12Ala
1431 C.T
820 C.T
0.0
0.3
0.0
(0.6,0.6)
(0.9,0.3)
(0.6,0.6)
0.5
0.4
0.1
(1.4,2.3)
(2.3,1.5)
(1.7,1.8)
0.87
0.59
1.00
0.13
PPARG3 681C.G 0.5 (1.0,0.0) 0.1 (1.0,1.2) 0.14
SREBF1 17 C.G 0.0 (0.6,0.5) 0.1 (0.9,0.7) 0.96
WAC 829 A.G 0.3 (0.9,0.4) 0.4 (0.3,1.2) 0.09
HSD11B1 2940 G.A 0.8 (0.0,1.6) 3.1 (3.1,9.4) 0.11
LIPC 644 A.G
557 C.T
0.2
0.2
(0.3,0.8)
(0.8,0.3)
0.5
0.9
(0.4,1.3)
(0.5,2.3)
0.48
0.27
0.38
IGF2 1926 C.G
ApaI A.G
6815 A.T
0.1
0.1
0.0
(0.4,0.6)
(0.4,0.7)
(0.5,0.5)
0.5
0.8
0.5
(0.4,1.4)
(0.2,1.7)
(0.5,1.4)
0.54
0.26
0.60
0.73
KCNJ11 Glu23Lys 0.5 (1.0,0.1) 0.3 (0.6,1.1) 0.09
ENPP1 IVS20delT-11
Lys121Gln
1044 A.G
0.3
0.2
0.4
(0.9,0.2)
(0.3,0.8)
(0.1,1.0)
0.0
1.3
0.6
(1.2,1.3)
(0.6,3.1)
(0.4,1.7)
0.45
0.33
0.21
0.04
ADIPOQ 11377 C.G
þ45 T.G
þ276 T.G
11391 G.A
0.1
0.1
0.3
0.2
(0.4,0.6)
(0.5,0.8)
(1.1,0.6)
(0.5,0.8)
0.2
0.6
0.0
0.5
(0.9,1.3)
(2.0,0.8)
(0.9,0.8)
(3.1,4.1)
0.89
0.62
0.67
0.88
0.50
CD36 178 A.C 0.4 (0.3,1.1) 0.5 (0.3,1.2) 0.43
IL6 174 G.C 0.0 (0.6,0.5) 0.0 (0.8,0.7) 0.99
TNFa 308 G.A 0.6 (0.0,1.1) 0.9 (0.8,2.6) 0.13
SERPINE1 675insG 0.1 (0.7,0.5) 0.3 (1.0,0.4) 0.70
WL (in kg) is adjusted for gender, diet group, age (linear and squared), baseline weight (separate effect for men and women), and centre (Gaussian random effect).
aA positive value of the estimated WL difference indicates a greater WL in individuals carrying the particular SNP than in noncarriers of the gene.
bThe test for association between the haplotypes of the genes where more than one SNP were genotyped is carried out as a global test for the possible haplotypes (see Methods
section for details).
CI, confidence intervals; SNP, single nucleotide polymorphism.
DOI: 10.1371/journal.pctr.0010012.t003..
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are no indications in these results of a major inﬂuence of any
of these genetic polymorphisms on the clinical outcome of
the intervention. When considering the several dimensions of
multiple testing carried out to address this subject, the few
statistically signiﬁcant results, obtained without any adjust-
ment for the multiple testing, should only be considered as
leads to new hypotheses about effects of speciﬁc genetic
polymorphisms that need to be addressed in subsequent
studies. Thus, the study suggests that SNPs in the PCSK1,
WAC, HSD11B1, and TNFa, genes and possibly haplotypes of
the GAD2 and ENPP1 genes may modulate diet-induced
weight changes, and that the effect of dietary fat content may
depend on SNPs in the SLC6A14, KCNJ11, ENPP1, ADIPOQ,
and TNFa genes.
The problem of multiple testing of the genotype-pheno-
type relationships has no unambiguous quantitative solution.
On one hand, there are clearly elements of testing of null
hypotheses that could not be distinguished on prior reasons
that make it unjustiﬁable to consider each single statistical
test independently of all the others. On the other hand, it may
not be justiﬁed to consider all tests as tests of the same null
hypothesis, in which case conventional quantitative adjust-
.......................................................................................................................................................................................
Table 4. Effects of Genotype–Diet Interactions on Weight Loss (WL) following 10-week Dietary Intervention, Aiming at Reducing the
Energy Intake by 600 kcal Either by a Low-Fat or a High-Fat Diet Allocated at Random to 642 European Obese Women and Men
Gene Single Nucleotide
Polymorphism (SNP)
Heterozygous Homozygous Single SNP
Test
Haplotype
Testc
WLb CI WLb CI p p
SLC6A14 Womena þ22510 C.G 1.9 (0.3; 3.5) 1.6 (0.1; 3.2) 0.06
SLC6A14 Mena þ22510 C.G — — 0.3 (2.0; 2.7) 0.78
CART 3608 T.C
1702 C.T
175 A.G
1336 delA
0.9
1.0
0.5
0.6
(2.1; 0.3)
(2.1; 0.1)
(1.7; 0.8)
(0.8; 1.9)
0.5
0.2
0.5
1.0
(1.9; 0.9)
(1.2; 1.6)
(1.9; 0.9)
(4.4; 6.5)
0.36
0.10
0.72
0.68
0.66
GHSR 447 C.G 1.1 (1.3; 3.6) — — 0.35
GAD2 þ83897 T.A
þ61450 C.A
243 A.G
0.6
0.1
0.1
(0.5; 1.7)
(1.0; 1.1)
(1.0; 1.3)
0.2
0.6
0.6
(2.6; 2.1)
(2.4; 1.2)
(1.9; 3.0)
0.56
0.78
0.88
0.80
GHRL Leu72Met 0.8 (0.8; 2.4) 3.8 (2.5; 10.1) 0.33
MKKS Arg517Cys 0.5 (0.8 ; 1.7) — — 0.47
LEPROTL1 2625 C.T 1.4 (0.4 ; 3.2) — — 0.12
PCSK1 T690S C.G 0.4 (0.7; 1.4) 0.5 (1.5; 2.4) 0.76
UCP2 866 G.A 0.8 (1.9; 0.3) 0.2 (1.4; 1.8) 0.25
UCP3 55 C.T 0.2 (1.3; 0.8) 0.2 (1.8; 2.2) 0.86
FOXC2 512 C.T 0.2 (1.7; 1.4) 0.5 (2.1; 1.1) 0.75
PPARGC1A Gly482Ser
þ2962A/G
1.2
0.2
(2.8; 0.5)
(1.4; 1.0)
1.0
0.7
(2.6; 0.7)
(0.7; 2.1)
0.39
0.36
0.23
PPARG2 Pro12Ala
1431C.T
820 C.T
0.3
0.6
0.3
(0.9; 1.5)
(0.6; 1.8)
(0.9; 1.5)
0.1
1.3
0.2
(3.8; 4.1)
(5.2; 2.5)
(4.0; 3.5)
0.88
0.45
0.87
0.94
PPARG3 681C.G 0.3 (1.4; 0.7) 0.3 (1.9; 2.5) 0.76 0.94
SREBF1 17 C.G 0.2 (1.2; 0.9) 1.4 (3.0; 0.2) 0.20
WAC 829 A.G 1.2 (2.5; 0.1) 1.2 (2.6; 0.3) 0.17
HSD11B1 2940 G.A 0.6 (1.0; 2.1) — — 0.49
LIPC 644 A.G
557 C.T
0.7
0.4
(1.8; 0.4)
(1.5; 0.6)
0.3
0.8
(2.0; 1.4)
(3.7; 2.1)
0.42
0.67
0.58
IGF2 1926 C.G
ApaI A.G
6815 A.T
0.8
0.6
0.1
(1.9; 0.3)
(1.6; 0.5)
(1.1; 1.0)
0.2
0.3
0.6
(2.0; 1.6)
(2.1; 1.5)
(1.3; 2.5)
0.34
0.59
0.77
0.41
KCNJ11 Glu23Lys 0.7 (0.3; 1.8) 1.7 (0.1; 3.4) 0.10
ENPP1 IVS20 del T 11
Lys121Gln
1044 A.G
0.5
0.2
0.1
(1.5; 0.5)
(1.4; 0.9)
(1.0; 1.2)
0.6
0.9
2.1
(3.1; 2.0)
(4.5; 2.8)
(4.2; 0.0)
0.62
0.85
0.13
0.55
ADIPOQ 11377 C.G
þ45 T.G
þ276 T.G
11391 G.A
1.2
1.1
1.5
1.6
(0.2; 2.3)
(2.4; 0.1)
(0.1; 3.2)
(3.0; 0.2)
1.0
0.6
0.8
0.9
(3.1; 1.2)
(2.2; 3.4)
(0.8; 2.4)
(8.6; 6.8)
0.029
0.18
0.14
0.07
0.43
CD36 178 A.C 0.4 (1.0; 1.8) 1.0 (0.5; 2.5) 0.42
IL6 174 G.C 0.6 (0.6; 1.8) 0.4 (1.1; 1.9) 0.60
TNFa 308 G.A 1.5 (0.3; 2.6) 0.1 (3.8; 3.6) 0.04
SERPINE1 675 insG 0.8 (0.5; 2.0) 0.1 (1.6; 1.3) 0.29
WL (in kg) adjusted for gender, age (linear and squared), baseline weight (separate effect for men and women), and centre (Gaussian random effect). The WL is the difference in excess
WL by low-fat diet compared with high-fat diet between individuals with the particular genotype and noncarrier individuals.
aSLC6A14 results are presented separately for men and women since the SNP is located on chromosome X.
bA positive value of the estimated WL difference indicates a greater WL on the low-fat diet than on the high-fat diet in individuals carrying the particular SNP than in noncarriers of the
gene.
cThe test for association between the haplotypes of the genes where more than one SNP were genotyped is carried out as a global test for the possible haplotypes (see Methods
section for details).
DOI: 10.1371/journal.pctr.0010012.t004..
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ment by, for example, the Bonferroni method would be
justiﬁed. However, the number of statistically signiﬁcant tests
at p¼0.05 was about what would be expected under repetitive
testing of the same null hypothesis. This suggests that any of
the statistically signiﬁcant ﬁndings must be cautiously
interpreted and only used as basis for new studies of the
possible role of these genetic polymorphisms.
The present study has limitations regarding both the
genotypes and the phenotypes. The analysis of SNPs in the
candidate genes took place without control of the possibly
associated variation in the genomic context. Despite the
control for population origin by centre, there may still be
population stratiﬁcation that can produce false effects or
obscure the true effects. Moreover, any ﬁndings of genotype
effects may reﬂect that the particular SNP is in linkage
disequilibrium with other SNPs within the locus or even in
the neighbouring chromosomal region, extending beyond the
haplotypes of the particular genes tested; and these other
SNPs may, in fact, be responsible for the observed effects. The
criteria for selection of the SNPs were not based on prior
evidence suggesting a speciﬁc functional role in dietary-
induced WL, which was not available. For several SNPs, the
homozygotes were so uncommon that estimates of recessive
effects or distinction between dominant and co-dominant
effects were impossible, which is also reﬂected in the width of
the CIs. For these SNPs, the analytical focus is on the general
nonspeciﬁed and/or the dominant genetic models. The
speculative possibility that the effect of the SNPs in one gene
may depend on genetic sex differences or on the presence of
particular SNPs in another gene (gene-gene interactions or
epistasis) could not be adequately addressed in the present
study, but the genotype distributions in men and women and
in the two randomised diet groups were almost similar.
Finally, the selection of SNPs in the candidate genes may not
provide a comprehensive coverage of the steadily evolving
knowledge about the genetic variation in these genes, so we
cannot exclude the possibility that other SNPs, not in linkage
disequilibrium with those investigated, in some of the genes
may have an inﬂuence on the clinical outcomes.
Not all individuals enrolled in the NUGENOB trial
completed the dietary intervention or strictly met the
recruitment criteria, but previous analysis, using imputation
of the missing values and sensitivity analysis have shown that
the overall results of the two diets on WL are quite robust
[13]. Moreover, the genotype distributions were almost
similar in these subgroups. We therefore ﬁnd it unlikely that
the inclusion of the participants not fulﬁlling the recruitment
criteria or the restriction of the present study to those
completing the dietary intervention has caused any bias in
assessment of the role of the genetic variation on WL. On
average, targets set for dietary changes were achieved, as also
veriﬁed by the average WL and the diet-dependent differ-
ences in changes in blood lipids [13], but there were
considerable individual differences in reported dietary
intake, both with regard to energy restriction and dietary
composition (see Table 2). It is possible that differences in
actual intake have obscured some main effects or interaction
effects of the SNPs on the WL, but the likely measurement
errors in reported dietary intake prohibit a valid search for
such effects. The study period is limited to 10 wk, and the
.......................................................................................................................................................................................
Table 5. Statistically Significant Associations (without Adjustment for Multiple Testing Effects)
Gene SNP Diet
Interaction
Genetic
Model
WL CI p
SLC6A14 Women þ22510 C.G Yes Dominant 1.8 (0.3; 3.3) 0.019
GAD2 þ83897 T.A, Ca
þ61450 C.A, Ca
243 A.G, Ca
No Haplotypea 0.4 (0.9; 0.0) 0.33b
PCSK1 T690S C.G No Dominant 0.5 (1.0; 0.0) 0.048
WAC 829a A.G No Recessive 0.6 (1.2; 0.0) 0.043
HSD11B1 G.A
G.A
No
No
Co-dominant
Dominant
0.8
0.8
(0.0; 1.6)
(0.0; 1.6)
0.039
0.047
KCNJ11 Glu23Lys Yes Co-dominant 0.8 (0.1; 1.6) 0.032
ENPP1 IVS20delT-11, Nca
Lys121Gln, NCa
1044 A.G, Ca
No Haplotypea 0.8 (0.1; 1.5) 0.04
ENPP1 1044 A.G Yes Recessive 2.1 (4.1; 0.0) 0.045
ADIPOQ 11391 G.A
11391 G.A
Yes
Yes
Co-dominant
Dominant
1.6
1.6
(2.9; 0.2)
(2.9; 0.2)
0.027
0.023
TNFa 308 G.A
308 G.A
308 G.A
308 G.A
No
No
Yes
Yes
Co-dominant
Dominant
Co-dominant
Dominant
0.5
0.6
1.0
1.4
(0.0; 1.0)
(0.0; 1.2)
(0.0; 2.0)
(0.3; 2.5)
0.046
0.048
0.047
0.015
Among particular genetic models (dominant, co-dominant, or recessive with regard to the effects of the single nucleotide polymorphisms) or haplotypes and weight loss (WL),
independent or dependent of interaction with the allocated diet in a 10-wk dietary intervention, aiming at reducing the energy intake by 600 kcal either by a low-fat or a high-fat diet
allocated at random to 642 European obese women and men.
WL (in kg) is adjusted for gender, diet group, age (linear and squared), baseline weight (separate effect for men and women), and centre (Gaussian random effect). A positive value of
the estimated difference in WL indicates a greater WL in individuals carrying the particular SNP or haplotype than in noncarriers. When there is an interaction with the diet, then the WL
is the difference in excess WL by low-fat diet compared with high-fat diet between individuals with the particular genotype and those not carrying the genotype.
aThe haplotypes listed are those indicated with Ca and Nca for carrier and noncarrier of the listed polymorphisms, and they were compared with a reference group of individuals who
had haplotypes not including any of the listed polymorphisms (see Methods section for details).
bFor the GAD2 haplotypes, there were no global statistically significant association, but the listed haplotype showed confidence limits not overlapping zero, wherefore it is included in
the table.
SNP, single nucleotide polymorphism.
DOI: 10.1371/journal.pctr.0010012.t005..
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energy restriction was moderate, so it is possible that the
more prominent gene-diet interactions may emerge by more
severe energy restriction (e.g., by very-low-calorie diets), or
during more prolonged intervention and weight maintenance
diet. On the other hand, current management strategies for
obesity do aim at rather moderate WL as clinically relevant
goals [59,60]. Furthermore, it is possible that interactions
between genes and diet composition may depend on whether
or not there is a concomitant dietary energy restriction. The
phenotype analysed is a composite phenotype, and although
the average changes in anthropometrics and body composi-
tion were similar in the two diet groups [13], the genotype
effects on the reduction of adipose tissue mass at various sites
(i.e., general versus peripheral and abdominal sites) may be
different. The study size did not allow a more detailed
analysis of differential effects of the genotypes by differences
in other characteristics, including those adjusted for in the
analysis, (e.g., gender, age and baseline body weight).
Generalisability
The study population originates from various parts of Europe
that have different obesity prevalence rates. It can thus be
assumed to be rather heterogeneous with respect to the
genetic and/or the environmental factors that may inﬂuence
body weight regulation. Analysis of the allele distribution of
the genes tested in the present study has shown that there is
great genetic heterogeneity between the populations from
the various participating sites (C. Dina et al., unpublished
data). We adjusted the analysis (using random effects models)
for confounding because of such differences, which, however,
assumes that the gene-diet interaction as such is not modiﬁed
by factors that differ among the various parts of Europe.
The fairly strict inclusion criteria as well as the recruitment
basis and procedures may have implications for the general-
isability of the results. One obvious such limitation is
illustrated by the predominance of women in the trial. On
the other hand, this and other aspects of the characteristics of
the participants in the trial are likely to represent the patient
population seeking dietary treatment for their obesity
problem. We have no prior reasons to believe that any of
the constraints on the study population would modify the
results of the study.
Overall Evidence
In the NUGENOB trial, we found almost equal mean WL in
the two diet groups, but there was a considerable interindi-
vidual variation in WL [13], to which genetic variation may
contribute. However, the observed effects of the SNPs in the
genes were moderate and the ﬁndings need to be further
investigated before they can be considered contributing to
the individual variation in WL during dieting.
Thus, these results do not contribute evidence to future
optimisation of dietary treatment of obesity by tailoring the
diet to the individual patients according to genotypes that
may predict the outcome of the treatment. Although the range
of observed WL differences does have clinical signiﬁcance
[59,60], the ﬁndings in the present study do not, by themselves,
lend support to such use of the genotypes in the panel of
genetic polymorphisms tested. When judged to be clinically
indicated, either of the dietary regimens investigated may be
used for inducing WL in obese individuals in accordance with
the previously reported results [13].
Most effects were compatible with dominant and/or
additive co-dominant effects, and only SNPs in the ENPP1
and WAC genes had recessive effects, which also were less
likely to be discovered because of the lower frequency of
homozygotes for the particular variant. The SNPs in the
HSD11B1, TNFa, and the WAC genes and a haplotype of
ENPP1 increased the WL, whereas the SNPs in the GAD2 and
PCSK1 genes reduced the WL. The SNPs in the SLC6A14,
KCJN11, and TNFa lead to an increased WL by a low-fat diet
compared to a high-fat diet, whereas SNPs of the ENPP1 and
ADIPOQ had the opposite effect.
The genes in which signiﬁcant effects of the SNPs were
observed belonged to several different categories of pre-
sumed function in the obesity-related phenotypes (see Table
2). The SLC6A14 and PCSK1 genes and possibly GAD2 are
presumed to inﬂuence hypothalamic regulation of appetite
[15,17–19]. The WAC gene may be involved in regulation of
adipocyte differentiation and function [38]. Several of the
genes presumed to be associated with regulation of lipid and
glucose metabolism (the HSD11B1, IGF2, KCJN11, and ENPP1
genes) [39,42–46] and the production of adipocytokines (the
ADIPOQ and TNFa genes) [47,48,52,53] were involved.
Surprisingly, the SNPs in the candidate genes affecting
efﬁciency of energy expenditure (UCP2 and UCP3) showed
no effects. Clearly, a better understanding of the speciﬁc roles
of the SNPs of these genes in altering the function of the
multiple, possibly interacting pathways, involved in produc-
ing the WL by the particular diets, will require further
exploration of how the SNPs affect the intermediate
phenotypes, possibly also during overfeeding and weight
gain. The differences in effects on WL and the statistical
strength of the various SNPs were rather small, so the impact
of the SNPs on dietary-induced WL may primarily depend on
the frequency of the variant allele, which was highest for the
WAC, SLC6A14, and KCNJ11 genes, which, for this reason, may
deserve particular attention.
The problems in interpretation of the ﬁndings in the
present study encourage considerations of how the potential
of the modern access to the genomic information may be
used in the future in such clinical studies, as also exempliﬁed
in a recent large-scale study of candidate genes associations
to type 2 diabetes [61]. In addition to the obvious request of
greater sample sizes, possibly by replication of the study
(which may be very challenging and expensive) it should be
considered to reduce the statistical noise in the assessments
of the correlations and associations between genotypes and
phenotypes. A variety of approaches may be employed,
including reﬁned deﬁnitions of genotypes and phenotypes,
better control of background genetic and environmental
factors also inﬂuencing the phenotype at interest, better
study designs and methods for measurements of phenotypes,
and further developed statistical tools for handling multiple
testing. Identiﬁcation of intermediate phenotypes closer to
the pathway steps to the genes combined with better
knowledge about both within and between locus interactions
of the genetic variants may both reduce the statistical noise
and yield a deeper insight into how the genes operate and
how the genetic variation eventually inﬂuences the clinically
relevant phenotype.
In conclusion, the results of the present study suggest that
polymorphisms in several genes associated with obesity-
related phenotypes did not have any major impact on weight
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reduction during short-term either high-fat or low-fat hypo-
energetic diet in obese participants, as implemented in the
present study. Thus, the results as such do not provide
evidence to support revision of current dietary treatment
regimens for obesity on the basis of individual genotyping.
The results gave tentative leads that some genetic poly-
morphisms may modulate the diet-induced WL, but this
needs to be conﬁrmed and further explored in future studies.
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